RhumbLine Advisers’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

RhumbLine Advisers’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-86,095	Closed	-$2.08M	–	4416
2023 Q1	$2.08M	Buy	86,095 +4,804	+6%	+$60.3K	﹤0.01%	1788
2022 Q4	$859K	Buy	81,291 +6,427	+9%	+$51.9K	﹤0.01%	2215
2022 Q3	$337K	Buy	74,864 +8,116	+12%	+$37K	﹤0.01%	2682
2022 Q2	$267K	Sell	66,748 -4,190	-6%	-$19.9K	﹤0.01%	2818
2022 Q1	$519K	Sell	70,938 -6,728	-9%	-$40.2K	﹤0.01%	2409
2021 Q4	$436K	Buy	77,666 +351	+0.5%	+$2.23K	﹤0.01%	2568
2021 Q3	$495K	Buy	77,315 +1,238	+2%	+$7.96K	﹤0.01%	2547
2021 Q2	$641K	Buy	76,077 +21,338	+39%	+$172K	﹤0.01%	2442
2021 Q1	$574K	Sell	54,739 -1,015	-2%	-$14.3K	﹤0.01%	2427
2020 Q4	$944K	Buy	55,754 +4,967	+10%	+$74.5K	﹤0.01%	2159
2020 Q3	$652K	Sell	50,787 -5,985	-11%	-$75.6K	﹤0.01%	2169
2020 Q2	$801K	Buy	+56,772	New	+$717K	﹤0.01%	2134

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

RhumbLine Advisers's PRVB Position: Q2 2023 in Review

RhumbLine Advisers sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 86,095 shares — an estimated $2.08M sold.

RhumbLine Advisers first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $2.08M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

RhumbLine Advisers reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
RhumbLine Advisers sold 86,095 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $2.08M.
RhumbLine Advisers first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
RhumbLine Advisers's Provention Bio, Inc. Common Stock position peaked at $2.08M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on RhumbLine Advisers's 13F filing for Q2 2023, filed 8 Aug 2023.